Dr. Gerstein is an endocrinologist and Professor at McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada, where he holds the Population Health Research Institute (PHRI) Chair in Diabetes. Dr. Gerstein pioneered and firmly established international long-term diabetes-focused outcomes trials as the norm to support Evidence-Based Diabetes Care. Randomized Control Trials (RCTs) that he designed and led have collectively included more than 90,000 people with either diabetes or prediabetes to date, and have studied and identified clinically important, life-saving diabetes therapies. His research has been published in over 550 papers and his h-index is 95. Dr. Gerstein played a major leadership role in HOPE, MICRO HOPE, ACCORD, DREAM, EpiDREAM, ORIGIN, TIDE, ACE, ELIXA, REWIND and AMPLITUDE O, among others. His work has been recognized by many awards, including the 2022 American Diabetes Association’s Outstanding Achievement in Clinical Diabetes Research Award.